Lord, Abbett & Co
PTLA

Lord, Abbett & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Lord, Abbett & Co’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-213,903
Closed -$11M – 975
2015
Q4 		$11M Buy
+213,903
New +$10.4M 0.03% 577

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co's PTLA Position: Q1 2016 in Review

Lord, Abbett & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 213,903 shares — an estimated $11M sold.

Lord, Abbett & Co first reported a position in PTLA in Q4 2015 and held it in 1 quarter. The position peaked at $11M in Q4 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

  • Lord, Abbett & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Lord, Abbett & Co sold 213,903 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $11M.
  • Lord, Abbett & Co first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Lord, Abbett & Co's Portola Pharmaceuticals, Inc. position peaked at $11M in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on Lord, Abbett & Co's 13F filing for Q1 2016, filed 16 May 2016.